CLINICAL TRIAL SUMMARY

MDACC Study No:SWOGS1211 (clinicaltrials.gov NCT No: NCT01668719)
Title:A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Principal Investigator:Robert Orlowski
Treatment Agent:Bortezomib; Dexamethasone; Elotuzumab; Lenalidomide
Study Status:Closed
Study Description:The goal of Phase 1 of this clinical research study is to find the highest
tolerable dose of elotuzumab that can be given in combination with bortezomib,
lenalidomide, and dexamethasone to patients with MM.

The goal of Phase 2 of this study is to learn if adding elotuzumab to the
combination of bortezomib, lenalidomide, and dexamethasone can help to control
MM.

Bortezomib is designed to block a protein that plays a role in how cancer cells
divide. This may affect cell function and growth and may cause cancer cells to
die.

Lenalidomide is designed to change the body's immune system. It may also
interfere with the development of tiny blood vessels that help support tumor
growth. Therefore, it may decrease or prevent the growth of cancer cells.

Dexamethasone is a corticosteroid that is similar to a natural hormone made by
your body. Dexamethasone is often given to MM patients in combination with
other chemotherapy to treat cancer.

Elotuzumab is a type of protein called a monoclonal antibody that is designed
to attach to a protein on the surface of MM cells, which may cause them to die.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I/Phase II
Treatment Agents:Bortezomib
Dexamethasone
Elotuzumab
Lenalidomide
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Robert Orlowski
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults